- Data compare Rebif vs. Tecfidera® and Aubagio® in the first year of treatment - Assessments include likelihood of relapse, medical costs and outpatient management resources needs 09:00 ET from EMD Serono ROCKLAND, Mass., June 2, 2016 ... PR Newswire, 4 weeks ago
EMD Serono Release: New Data At Assess Real-World Impact Of Rebif (Interferon Beta-1a) In People With Relapsing MS - BioSpace, 4 weeks ago
1 images for "Tecfidera Treated Patients"
Biogen tumbled 12 percent in Tuesday trading after the biotechnology company said that a multiple sclerosis treatment with the potential to be a blockbuster drug failed to meet key goals in a midstage study. In testing, opicinumab failed to ...Bioscience Technology Online, 3 weeks ago Biogen's MS drug misses main goal in mid-stage study Yahoo! India, 3 weeks ago Biogens MS drug misses main goal in mid-stage study Reuters UK, 3 weeks ago FDA approves new Biogen multiple sclerosis drug Boston Globe, 1 month ago
More from: Reuters UK, Reuters UK...and 6 other sources
Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 6, Authorised
This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...European Medicines Agency, 2 weeks ago
There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...DrugInjuryLaw.com, 1 month ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice Drug Injury Watch, 1 month ago
AT THE AAN 2016 ANNUAL MEETING VANCOUVER (FRONTLINE MEDICAL NEWS) Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative ...PM 360, 2 weeks ago
/PRNewswire/ -- Revenue Forecasts for Leading Submarkets Including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and Also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif MS Drugs - Discover R&D ...WorldNetDaily, 2 weeks ago
Home Business News Share the joy Introduction I am a fervent believer that investors are best served by investing towards a specific investment objective that suits their own unique goals, objectives and risk tolerance.News EasyBranches.com, 2 weeks ago 5 Appealing Biotechnology Stocks for Healthy Long-term Returns Yahoo! Finance, 2 weeks ago
By Mark Terry , BioSpace.com Breaking News Staff With very little fanfare, Biogen ( BIIB )'s chief information officer, Matt Griffiths , left the company after only a year-and-a-half. No reason was given. In May 2015, Biogen announced that ...BioSpace, 2 weeks ago Biogen Loses $8 Billion in Market Value in One Day Pharma Live, 3 weeks ago
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma's continued ...Pharma Live, 3 weeks ago
Popular Posts: Recent Posts: How do you make $8 billion vanish in an instant? One way is to develop a multiple sclerosis drug that doesn't work as well as hoped. Just ask Biogen Inc ( BIIB ) investors, who saw the value of BIIB stock slump ...InvestorPlace.com, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!